Cancer and TNF antibodies boost Biologics Sales in 2007(04/01/2008) The Business Intelligence firm La Merie S.L. reported that for the first time erythropoietins have been superseded by the major cancer antibodies Rituxan, Herceptin, Avastin and Erbitux as the number one top selling class of biologics with the ...
2008 is a decisive year for the validation of the asthma target interleukin-13(02/15/2008) Results of two major phase II studies in asthma expected during 2008 will be a GO/NO GO milestone for the field of interleukin-13 (IL-13) antagonists The Business Intelligence firm La Merie S.L. reported that during the year 2008 results of major phase II studies in asthma with two different interleukin-13 antagonistic antibodies are expected which will be decisive for the validation of a hot ...
Biologics define new standard of therapy in psoriasis(09/12/2006) La Merie S.L. reported that the advent of anti-TNF biologicals has set a new standard of treatment in moderate to severe plaque-type psoriasis. Systemic anti-TNF biologics etanercept followed by infliximab, adalimumab and certolizumab pegol have ...
The Crowded Field of VEGF and VEGF-R Targeting Drugs(08/18/2006) The Business Intelligence firm La Merie S.L. reported that the versatility of the validated VEGF and VEGF-R target and its tractability for all kinds of drug classes has filled the pipeline of VEGF agonists, VEGF/VEGF-R antagonists and VEGF-R ...
A Full Pipeline of Follow-on TNF-Antagonists(08/03/2006) The US$ 7.6 bln market of TNF-antagonists attracts numerous follow-on compounds The Business Intelligence firm La Merie S.L. reported that the huge market of US$ 7.6 bln in 2005 and the clinical validation of the target in many inflammatory indications has filled the pipeline of follow-on TNF-antagonists. Sales of the three ...
Biogenerics and new technologies compete with 1st generation major protein products(06/21/2006) The Business Intelligence firm La Merie S.L. reported that the US$ 32 bln market of major protein products with commencing patent expiry is endangered by generic products and by innovator solutions including engineered molecules and drug delivery ...
Top